Benign Breast Disease: Toward Molecular Prediction of Breast Cancer Risk
Abstract
Optimal early detection and prevention strategies for breast cancer are predicated on our ability to identify individuals at significantly increased risk for this disease. Unfortunately only a minority of the 200,000 women who are diagnosed with breast cancer in the US each year are recognized as being at significantly increased risk. The purpose of this Center is to bring molecular risk prediction for breast cancer into the clinical arena. This will require progress on three fronts of scientific endeavor: (i) Establishment of a tissue repository of benign breast disease; (ii) Assessment of potential biomarkers of risk in this tissue set and (iii) Discovery of new, potentially relevant biomarkers of risk. We have made good progress on our tissue repository and have begun our biomarker studies. We completed the follow-up of the 1982-91 group (n = 5,181) and are in process with the 1967-81 group (n = 6,102). A total of 762 cases of breast cancer were identified in this 25 year cohort. We established a relational database in which data are entered on an ongoing basis. Benign histopathology has been characterized for 80% of the 25 year cohort. We have begun the process of collecting fresh tissue for culturing in vitro.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2004
- Accession Number
- ADA427975
Entities
People
- Lynn C. Hartmann
Organizations
- Mayo Clinic